Boston Scientific Liberty Stent Groomed To Face Next-Gen Cobalt Competitors
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will enroll approximately 400 patients in an ongoing clinical trial to support a PMA supplement for the firm's Taxus Liberty stent platform
You may also be interested in...
Conor Medsystems, Biotronik DES Would Compete With Established Players
Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific
Conor Medsystems, Biotronik DES Would Compete With Established Players
Conor Medsystems expects technological characteristics - not price - will successfully position its CoStar drug-eluting stent against offerings from Johnson & Johnson and Boston Scientific
Divide And Conquer: Boston Scientific Plots Strategy To Segment DES Market
Boston Scientific plans to protect its projected share of the drug-eluting stent market by making Taxus the first DES to earn a series of sub-population indications